20/20 Biolabs, Inc. (AIDX)
↓ Download CSV- Sector Services
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, 20/20 Biolabs, Inc. reported revenue of $2.05M, up 16.7% from the prior year. The company ran a net loss, with a net margin of -182.8% and a gross margin of 29.6%. It held $4.14M in total assets against $4.16M in total liabilities.
Key ratios (FY2025)
29.6%
Gross margin
-162.9%
Operating margin
-182.8%
Net margin
+16.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $2.05M | $1.75M | — |
| Cost of Revenue | $1.44M | $1.39M | — |
| Gross Profit | $604.5K | $360.3K | — |
| Operating Income | -$3.33M | -$5.68M | — |
| Net Income | -$3.74M | -$5.55M | — |
| EPS (Diluted) | $-0.76 | $-1.16 | — |
| Total Assets | $4.14M | $3.58M | — |
| Total Liabilities | $4.16M | $2.08M | — |
| Shareholders' Equity | -$19.2K | $1.51M | $4.29M |
| Cash & Equivalents | $1.03M | $1.78M | — |
| Operating Cash Flow | -$1.92M | -$2.60M | — |
| Shares Outstanding | 5.44M | 4.82M | — |